Objectives. This study attempted to evaluate whether neurohumoral activation at the time of hospital discharge in postinthreflon patients helps to predict long-term prognosis and whether long-term therapy with the angicitensin-converting enzyme inhibitor captopril modifies this relation .
Results. By univariate analysis, activation of plasma renin activity and aldosterone, norepinephrine, atrial natriuretic peptide and arginine vasopressin levels were related to subsequent cardiovascular events, whereas epinephrine and dopamine levels were not . By multivariate analysis, only plasma renin activity (relative risk 1,6, 95% confidence interval 10 1 1 .0 to 2.5) and atrial natriuretic peptide (relative risk 21, 95% CI 1.3 to 3 .8) were independently predictive of cardiovascular morta ' whereas the other neurohormones were not. Only plasma renin activity and aldosterone, atrial natriuretic peptide and arginine vasopressin were independent predictors of the combined end points of cardiovascular mortality, development of severe heart failure or recurrent myocardial infarction. Except for 1-year cardiovascular mortality, the use of captopril did not significantly modify these relations .
Conclusions. Neurohumoral activation at the time of hospital discharge in postinfarction patients is an independent sign of poor prognosis . This is particularly true for plasma renin activity and atrial natriuretic peptide . Except for 1-year cardiovascular mortality, captopril does not significantly modify these relations .
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Activation of neurohumoral systems occurs during the first few days of an acute myocardial infarction (1) . However, by hospital discharge, activation of most systems has generally subsided (1, 2) . The exceptions are patients taking diuretic drugs or those with left ventricular dysfunction, where a significant proportion may have persistent activation of one neurohumoral system or another (1, 2) . The Survival and Ventricular Enlargement (SAVE) study (3) demonstrated that starting the angiotensin-converting enzyme inhibitor captopril a mean of 11 days after infarction resulted in long-term improvement in survival and a reduction in the risk of developing overt heart failure or of having a recurrent myocardial infarction . These findings, combined with the multiple studies indicating an improved survival and a decreased reinfarction rate when beta-adrenergic blocking agents are started around the time of hospital discharge (4) , suggest that postinfarction neurohumoral activation is deleterious and that its inhibition would be desirable . If so, one might expect neurohumoral activation at the time of hospital discharge to be associated with an increased risk and that as increase in, plasma renin activity would be particularly useful in identifying patients that would benefit from the use of angiotensin-converting enzyme inhibitors. Alternatively, predischarge neurohumoral activation could be a poor reflection of long-term activation and, as occurs in hypertension (5) , angiotensin-converting enzyme inhibitors may be useful regardless of plasma renin activity.
The questions addressed in this analysis were t) whether predischarge neurohumoral activation provides useful longterm prognostic information in postinfarction patients, and 2) whether captopril modifies this relation. This was accomplished by measuring plasma renin activity and aldosterone, norepinephrine, epinephrine, dopamine, arginine vasopressin and atrial natriuretic peptide levels a mean of 12 days after infarction in 534 patients before randomization to the SAVE study . Activation of each neurohormone was then related to subsequent cardiovascular mortality, reinfarction or the development of severe heart failure . Finally, we assessed the interaction between these neurohumoral variables and the magnitude of the reduction in cardiac events by long-term treatment with captopril .
Methods
Patients. The 534 patients included in this study were participants in the SAVE study (3), a randomized, multicenter trial that demonstrated that the angiotensin-converting enzyme inhibitor captopril, where started 3 to 16 days after infarction, improved survival in patients with left ventricular dysfunction (defined as left ventricular ejection fraction !540%).. Exclusion criteria included contraindications to captopril and concurrent medical problems, such as renal insufficiency (creatinine >2.5 mg/dl), severe valvular heart disease, refractory hypertension, overt heart failure or heart failure requiring vasodilator therapy, malignancy or other conditions thought to limit survival; geographic problems ; or inability to give informed consent (3) . Patients with isehemic symptoms or with a markedly positive exercise test were also excluded from the study unless a cardiac catheterization and appropriate revascularization procedures were conducted before randomization . Patients who agreed to participate in the neurohumoral component of SAVE signed an informed consent agreeing to have extra blood samples drawn for these assays .
Ten Canadian and three American centers participated in this substudy . Patient recruitment for this substudy began November 1, 1988 and ended January 28, 1990 . Blood samples were obtained before randomization a mean of 12 days (range 3 to 16 days) after myocardial infarction . Thirty-eight agematched subjects (mean (±SD] age 57 ± 7years ; 14women, 24 men) who were not SAVE participants were used as control subjects. Control subjects were chosen from the various par-JACC Vol . _24, No . 3 Sepecniter 199-1:953-c1 ticipating centers, had no known disease and were receiving no medication . Neurohumoral samples were obtained front these control subjects and were handled in a manner identical to those of the SAVE patients .
Seventy of the 534 patients participating in the substudy had revascularization procedures (31 had coronary artery bypass surgery, and 39 had coronary angioplasty) performed during the interval between their myocardial infarction and neurohumoral testing. Because' these patients' clinical, laboratory and neurohumoral values were similar to those of the other substudy patients, they were analyzed with the rest of the group.
Neurohuntorat measurements. After an overnight fast, an indwelling venous catheter was inserted, and the patient was permitted to rest in the supine position for 30 min . Blood was sampled for plasma renin activity and aldosterone, norepinephrine, epinephrine, dopamine, arginine vasopressin and atria( natriuretic peptide levels, Samples were centrifuged at 4°C and then frozen at -.gel°C and sent monthly to the central laboratory (Hospital du Sacrd-Coeur de Montreal) packed in dry ice . All sample transfers between peripheral and central laboratories took <24 h . No samples were delayed, hemolyzed or thawed. Neurohormones were measured as previously described (6) as soon as received to minimize the loss of atrial natriuretic peptide activity (7) . Patient follow-up. Surviving patients were followed up a mean of 38 ± 7 months (range 24 to 55) . An independent mortality committee assessed and classified deaths as to whether they resulted from cardiovascular disease . Severe congestive heart failure was defined as heart failure requiring hospital admission or clinical deterioration requiring the use of open-label angiotensin-converting enzyme inhibition . Recurrent myocardial infarction was defined as a clinical myocardial infarction by the participating center or the mortality committee .
Statistical analyses. All statistical analyses were performed using the Statistical Analysis System (SAS) . The data of participants who took part in this substudy of SAVE were collected on the standard SAVE study forms . The 38 control patients who were not" part of SAVE had data collected separately. The comparability of baseline characteristics in the two treatment groups was ascertained by unpaired two-sample t test for continuous variables and chi-square tests for categoric variables.
Cox proportional hazard analyses were used to investigate the relations between neurohumoral activation at the time of entry to SAVE and subsequent end points. For all Cox proportional hazard analyses, p values, relative risks and associated confidence intervals were determined . All analyses were performed using a significance level of alpha = 0 .05 (two-sided). The end points studied were total cardiovascular mortality, 1-year cardiovascular mortality, severe heart failure, recurrent myocardial infarction and, in addition, the combined end point of total cardiovascular mortality or severe heart failure or recurrent myocardial infarction were evaluated . These relations were analyzed by both univariate and multivariate approaches. The univariate analysis consisted of a Cox proportional hazard model with only one independent variable (tine neurohormone) . Evaluation of the relation between end points and neurohormones was first performed using neurohumoral levels as continuous variables . This was then repeated with dichotomized neurohormone levels (activation or not) . Ncurohumoral activation was defined as L-1 .96 SD above the mean levels of age-matched control subjects . The demographic and clinical variables used in the multivaria',C Cox proportional hazard analyses were chosen because of their strong univariate relations with the end points . These variables included age, gender, previous myocardial infarction, diabetes, hypertension, left ventricular ejection fraction and the use of thrombolytic therapy. To exp!ore how captopril modified these relations, Cox proportional hazard models were constructed with neurohumoral status and treatment effect and the interaction between neurohumoral status and treatment effect as the independent variables and the cardiovascular end points as the dependent variables.
Results
Patient characteristics . The characteristics of patients included in the neurohumoral substudy resembled those of patients in the main trial (2) . Also, as in the main trial (3), in this neurohumoral cohort there were no significant differences in clinical or demographic characteristics between patients randomized to receive captopril or placebo ( Table 1 ) . The average age was 60 ± 11 years, and 82% were male . The incidence of previous myocardial infarction (35%), diabetes (20%) and hypertension (30%) were relatively high . The mean maximal ROULEAU ET AL . POST) NF AP,('TION NEUROHORMONES AND PROGNOSIS Dala presented are mean values -SD or percent of patients, Neurohnniotal activation is a value -I .96 SD above time mean levels of age-matched control subjects. 17o = percent of patients . 585 increase in creatine phosphokinase during infarction was 13 .1 times the upper limit of normal . The Killip class with the index (SAVE) myocardial infarction was 1 in 58%,11 in 33%, 111 in 7% and IV in 2% . Left ventricular ejection fraction 31 ± 7% was low (SAVE required left ventricular ejection fraction {40% as an entry criteria) . Thrombolysis was used in 32% of patients. At the lime of ncurohumoral sampling, 37% of patients were receiving diuretic drugs, 34% were receiving beta-blockers, 41% were receiving nitrates, 28% were receiving digoxin, 27% were receiving calcium-channel blocking agents, and no patients were receiving angiotensin-converting enzyme inhibitors or other vasodilating agents . There was no difference in the frequency of these variables between the placebo and captopril groups.
Compared with age-matched control subjects, higher levels of plasma renin activity (2 .95 ± 3 .7 vs. 1 .2 ± 1 .2 ng/ml per h, p < 0 .001), aldosterone (27 ± 28 vs . 17 ± 7 ng/dl, p < 0 .001), norepinephrine (298 ± 192 vs . 221 ± 87 pg/ml, p < 0 .001), dopamine (28 ± 25 vs. 21 ± 7 pg/ml, p = 0.004), arginine vasopressin (1 .8 ± 6 .8 vs. 0 .7 ± 0.3 pg/ml, p < 0.001) and atrial natriurvic peptide (76 ± 75 vs . 21 ± 9 pg/ml, p < 0101) were observed, but epinephrine levels (36 ± 28 vs . 31 ± 16 pg/r,11, p = NS) were essentially the same . These higher levels were found in patients with and without diuretic drugs (2) . The percent of study patients with activation (?I .96 SD above the mean levels in age-matched control subjects) was greater for atrial natiuretic peptide than for other neurohormores ( Table  1 ) . The only difference in neurohumoral values between the placebo and captopril groups was higher plasma atria] natriuretic peptide values in the captopril group ( percent of patients with activation of atrial natriuretic peptide also tended to be higher in the captopril group, although it did not reach statistical significance (p = 0.07) .
As expected in these high risk postinfarction patients selected for depressed left ventricular function, the incidence of 1-year and total cardiovascular mortality was relatively high ( Table 2 ). This was also true for the development of severe heart failure, recurrent myocardial infarction and the combined end point of heart failure, recurrent myocardial infarction or cardiovascular mortality . Despite the similarities in baseline characteristics between the placebo and captopril groups, patients randomized to receive captopril had a decrease in all evaluated end points. In the sample of SAVE patients included in this neurohumoral substudy, this decrease reached statistical significance for the end points of severe heart failure and the combined end point of severe heart failure, recurrent myocardial infarction or cardiovascular mortality.
of netunhumoral activation on end points. The univariate relations between neurohumoral activation (categoric values) (defined as L1 .96 SD above the mean levels in control' subjects) and subsequent end point events are presented in Table 3 . One -year cardiovascular mortality was associated with activation of plasma renin activity, aldosterone and atrial natriuretic peptide . Total cardiovascular mortality was associated with activation of all measured neurohormones, except for plasma epinephrine and dopamine . The development of severe heart failure was associated with activation of all neurohormones except plasma epinephrine, and recurrent myocardial infarction was associated with activation of arginine vasopressin and aldosterone . Activation of all neurohormones except for plasma epinephri and dopamine was associated with the; combined end point of cardiovascular mortality, severe heart failure or recurrent myocardial infarction . The univariate relations between neurohormone levels and the various end points were somewhat different when continuous values of the neurohormones were correlated to events rather than analysis according to whether neurohumoral activation was present or not. Specifically, arginine vasopressin was no longer correlated with any end point ; plasma norepinephrine levels were correlated with 1-year cardiovascular mortality (Wald chi-square 11 .1, relative risk 1 .37,95% confidence interval [CI] 1 .14 to 1.64, p < 0.001); and JACC Vol . 24, No. 3 September 1994 :583-91 plasma renin activity correlated with recurrent myocardial infarction (Wald chi-square 3.7, relative risk 1 .12,95% Cl 1.00 to 1 .25, p = 0.056) . Otherwise, the results using continuous neurohumoral levels resembled those using discrete categoric analyses (activation or not).
When activation (categoric values) of various neurohumoral systems was considered along with other variables known to modify survival (age, gender, previous myocardial infarction, hypertension, diabetes, thrombolysis and left ventricular ejection fraction) in multivariate analysis (Table 4 ), only activation of atrial natriuretic peptide remained significantly related to 1-year cardiovascular mortality. In addition, atrial natriuretic peptide, as well as plasma renin activity, continued to be associated with total cardiovascular mortality . Activation of norepinephrine, arginine vasopressin or aldosterone was no longer associated with total cardiovascular mortality . Activation of arginine vasopressin continued to be related to recurrent myocardial infarction, but aldosterone did not . Nevertheless, activation of all neurohormones, except for epinephrine, dopamine and perhaps aldorterone continued to be independently related to the development of severe heart failure. Plasma renin activity, atrial natriuretic peptide, arginine vasopressin and aldosterone also continued to be independently related to the combined end point of recurrent myocardial infarction, severe heart failure or cardiovascular death. When neurohumoral levels (as continuous values rather than according to whether a neurohonmone was activated or not) were correlated to the various end points by multivariate analyses, fewer relations between neurohormones and end point events were found. No relation between neurohormone levels and the individual end points of cardiovascular mortality, recurrent myocardial infarction or the development of severe heart failure could be found . Also, only plasma norepinephrine (Wald chi-square 5 .0, relative risk 1 .15,95%a1 .02 to 1 .31, p = 0.025) and aldosterone (Wald chi-square 3.9, relative risk 1 .03,95% CI 1 .00 to 1 .06, p = 0.049) were significantly associated with the combined end point of recurrent myocardial infarction, severe heart failure or cardiovascular mortality. The association between the combined end points and plasma renin activity approached significance (Wald chi-square 3.5, relative risk 1 .07,95% CI 1 .00 to 1 .14, p = 0.063) .
Effect of captopril . Table 5 demonstrates the relative risk associated with activation of a specific neurohormone in patients according to randomization to placebo or captopril . As one would expect from regard to the risk of subsequent cardiovascular morbidity and mortality. Of the neurohormones assessed, plasma atrial natriuretic peptide and plasma renin activity were the most useful. Although captopril attenuates neurohumoral activation (8) , and neurohumoral activation was associated with cardiovascular events in this study, captopril did not significantly modify the predictive value of neurohumoral activation . The JACC Vol . 24, No. 3 September 1994:583-91 only possible exception occurred for 1-year cardiovascular mortality, where the deleterious effect of activation of plasma renin activity or arginine vasopressin was eliminated by randomization to captopril .
Evaluation of the predictive value of the various neurohormones was performed using two different techniques . The first examined plasma levels as continuous values . This more traditional approach has the advantage of considering the actual values measured and of appreciating subtle differences between patients . However, it has the disadvantage of considering differences within the normal range in which the majority of our patients could be found and of being subject to variations that result from technical aspects, such as the preparation and transport related to the measurement of these neurohormones . Except for plasma norepinephrine, where continuous rather than categoric values appeared to be more predictive of cardiovascular events, this did not appear to be ihe preferred approach. This was particularly true when the effects of neurohormones on prognosis were assessed considering other important clinical variables (multivariate analyses) . By multivariate analysis, considering neurohormones as continuous values identified very few significant relations between neurohormones and cardiovascular end points, whereas evaluating neurohormones as activated or not (categoric approach) identified multiple significant relations . Although this categoric approach to analysis may miss graded or subtle effects of differences in neurohumoral levels, it minimizes informationless variability contained in continuous neurohumoral plasma levels by identifying only patients with marked activation oa a given neurohumoral system .
Prognostic value of various neurohormones. Plasma renin activity provided independent prognostic information with regard to total cardiovascular mortality, the development of severe heart failure and the occurrence of combined cardiovascular end points . The prognostic value of plasma renin activity in these postinfarction patients with left ventricular dysfunction is consistent with studies in patients with chronic left ventricular dysfunction and overt heart failure in whom an increase in plasma renin activity is associated with a high risk of subsequent events (9, 10) . However, in patients with chronic left ventricular dysfunction but no overt heart failure, because plasma renin activity is normal unless patients are receiving diuretic drugs the prognostic significance of plasma renin activity is less certain (11) . These findings coupled with the increase and prognostic significance of plasma renin activity in the SAVE population underscore the pathophysiologic differences that exist between the SAVE and Studies of Left Ventricular Dysfunction (SOLVD) prevention trial populations . Of all cardiovascular events, plasma renin activity was most closely associated with the development of heart failure . The reasons for this association are uncertain but are most likely related to angiotensin-Il-induced sodium and water retention, progressive ventricular dilation and left ventricular dysfunction caused by an angiotensin-11-induced increase in preload, afterload and protein synthesis (12, 13) . The association between plasma resin activity and recurrent myocardial infarction was less clear, with an association being found only *Neurohumoral activation was defined as values >_l .96 SD above mean levels in age-matched control subjects. Relative risk and p values were calculated for activation versus inactivation for each neurohormone based on Cox proportional hazard analysis. For each Cox proportional hazard model, the independent variables are treatment, neurohumoral activation and the interaction between treatment effect and neurohumoral activation . tWald chi-square and p values were calculated for the interaction term in each model . infarction. The reasons for an association between plasma renin activity and recurrent myocardial infarction are uncertain but may be related to the potent vasoconstrictor effect of angiotensin 11 (16) , to its atherogenic (17) and thrombogenic (18) effects and perhaps by other, still poorly understood genetically related mechanisms (19) .
Plasma aldosterone, whether it was considered a continuous or categoric value, was not an independent predictor of any one cardiovascular end point alone . Nevertheless, it was associated with the occurrence of the combined cardiovascular end points. These findings are consistent with previous reports (IC) demonstrating that an increase in plasma aldosterone is a sign of poor prognosis in patients with heart failure . Potential mechanisms proposed to explain a detrimental effect of aldosterone include increased cardiac fibrosis (20), hypokalemia and hypomagnesemia (21) . To what extent the adverse effects of aldosterone are independent of stimulation of the reninangiotensin systems is unknown. However, because of the relatively poor correlation between activation of one of these systems and the other (2), there is reason to believe that they are at least partially independent . In this study, nearly twice as many patients had activation of aldosterone compared with plasma renin activity . Plasma atrial natriuretic peptide provided independent information with regard to early and total cardiovascular mortality, development of severe heart failure and combined cardiovascular end points . Our findings at hospital discharge are consistent with the poor prognosis observed when atrial natriuretic peptide levels are acutely elevated after infarction (22) . These results are also consistent with those in patients with chronic heart failure, where atrial natriuretic peptide has been found to be a powerful predictor of subsequent mortality (23) . The mechanisms by which elevated atrial natriuretic peptide levels are associated with a poor prognosis are uncertain because atrial natriuretic peptide promotes vasodilation and diuresis and suppresses activation of the renin-angiotensin system (24) , effects associated with improvement rather than deterioration of the patient. Rather, it is most probable that elevated levels of atrial natriuretic peptide in themselves are not harmful but that their elevation merely reflects an unfavorable underlying pathophysiologic process. Finally, because the predictive value of atrial natriuretic peptide was independent of left ventricular ejection fraction, other mechanisms that lead to an increase in atrial natriuretic peptide, such as diastolic dysfunction, must be considered potentially important postinfarction risk factors .
By univariate analyses, plasma norepinephrine was found to be associated with all subsequent cardiovascular events except recurrent myocardial infarction . These associations were found variably when norepinephrine levels were examined as continuous or categoric (activated or not) values . However, when considered along with other important variables, the independent predictive value of plasma norepinephrine was substantially weakened, remaining significant for the development of severe heart failure and combined cardiovascular end points only . This differs from patients with chronic heart failure, where plasma norepinephrine is a major predictor of subsequent mortality after adjusting for other mortality correlates (25) . The reasons for this discrepancy are uncertain but may be related to the lower plasma norepinephrine levels in postinfarction patients compared with patients with chronic heart failure (I) . Other possible explanations are that circulating catecholamine levels do not adequately reflect adrenergic tone or that circulating levels around the time of hospital discharge do not JACC Vol. 24. No . 3 September 1944:583-91 faithfully reflect long-term activation in postinfaretion patients . That plasma epinephrine levels were unrelated to cardiovascular events suggests that postinfarction prognosis is unrelated to adrenergic activation by the adrenal glands . Little has been published with regard to plasma dopamine levels and prognosis ; however, it would appear from this study that it has little prognostic value in these patients . Nevertheless, because the use of beta-blockers has been found to be useful in these patient populations, further work investigating the relation between adrenergic activation and prognosis is warranted .
Arginine vasopressin emerged as a good predictor of subsequent cardiovascular events . By univariate analyses, it was associated with all cardiovascular events except 1-year cardiovascular mortality and, by multivariate analysis, it was predictive of development of severe heart failure, recurrent myocardial infarction and combined cardiovascular end points . These findings differ front those of patients with chronic heart failure, where arginine vasopressin has not been found to be a particularly useful prognostic index (26) . The reasons for these differences are uncertain but may be related to the far greater activation of this system in p ostinfarction patients compared with patients with symptomatic heart failure. The independent predictive value of arginine vasopressin for the occurrence of recurrent myocardial infarction was particularly impressive . One possible explanation is the coronary vasoconstrictor effects of vasopressin (27, 28) . Although the plasma levels of arginine vasopressin normally associated with vasoconstriction are greater than those observed in the vast majority of patients in this study, it is possible that in susceptible patients, lower levels cause coronary spasm. A second potential contributing mechanism is the smooth muscle proliferative effects of arginine vasopressin (29) .
Effect of captopril . Except for modifying the prognostic value of plasma renin activity and arginine vasopressin on 1-year cardiovascular mortality, captopril had little effect on the prognostic value of neurohormone levels on any of the measured end points. Also, because of the generally negative findings with captopril and the large number of statistical comparisons made, even these two relations must be taken with care . This is surprising considering the independent prognostic value of plasma renin activity in this study . These results also differ from reports of chronic heart failure, where the beneficial effects of angiotensin-converting enzyme inhibitors are concentrated in patients with the most neurohumoral activation, particularly of the renin-angiotensin system (10, 30) . The reason for this discrepancy is uncertain ; however, the possibility of low statistical power due to inadequate sample size must be considered . Because captopril appeared to eliminate the relations between plasma renin activity and early cardiovascular death, it is also possible that activation of the renin system is particularly deleterious in the earlier (first year) postinfarction period or that early postinfarction levels do not faithfully reflect long-term activation of this system . Finally, it is possible that the beneficial effects of captopril occur through mechanisms such as inhibition of tissue angiotensin-converting enzyme inhibitors or other angiotensin-converting enzyme inhibitor-related effects that may not necessarily be reflected by levels of circulating plasma renin activity . In any case, from this study it would appear that, in this respect, postinfarction patients resemble hypertensive patients, a situation where plasma renin activity does not necessarily predict the hypotensive response to angiotensin-converting enzyme inhibitors (5) .
Had patients with overt heart failure been included in this study it is possible that these relations would have differed and that neurohumoral activation would have better identified patients most likely to benefit from captopril therapy .
